Abstract：
UNASSIGNED: The Exacerbation of Chronic Obstructive Pulmonary Disease (ECOPD), especially if leading to hospitalization, increases the risk of death. Our scoping review aims to identify updated mortality risk factors for both short- and long-term periods.
UNASSIGNED: A comprehensive search, covering the period from January 2013 to February 2024, was performed to identify eligible studies that consider factors associated with death in hospitalized ECOPD. We considered short-term mortality, up to one year (including in-hospital mortality, IHM) and long-term mortality over one year, without time limits. We excluded studies concerning the intensive care area.
UNASSIGNED: We considered 38 studies, 32 and 8 reporting data about short- and long-term mortality, respectively. Two studies consider both periods. Several factors, some already known, others newly identified, have been evaluated and discussed. Some of these were related to the characteristics and severity of COPD (age, body mass index, lung impairment), and some considered the response to ECOPD. In this last context, we focused on the increasing role of biomarkers in predicting the mortality of patients, particularly IHM. Our factors associated with a worse prognosis may be helpful in clinical practice to identify patients at risk and, subsequently, determine a personalized approach.
UNASSIGNED: A comprehensive search, covering the period from January 2013 to February 2024, was performed to identify eligible studies that consider factors associated with death in hospitalized ECOPD. We considered short-term mortality, up to one year (including in-hospital mortality, IHM) and long-term mortality over one year, without time limits. We excluded studies concerning the intensive care area.
UNASSIGNED: We considered 38 studies, 32 and 8 reporting data about short- and long-term mortality, respectively. Two studies consider both periods. Several factors, some already known, others newly identified, have been evaluated and discussed. Some of these were related to the characteristics and severity of COPD (age, body mass index, lung impairment), and some considered the response to ECOPD. In this last context, we focused on the increasing role of biomarkers in predicting the mortality of patients, particularly IHM. Our factors associated with a worse prognosis may be helpful in clinical practice to identify patients at risk and, subsequently, determine a personalized approach.
摘要：
■慢性阻塞性肺疾病（ECOPD）的恶化，特别是如果导致住院，增加死亡风险。我们的范围审查旨在确定短期和长期更新的死亡风险因素。
■全面搜索，本研究涵盖2013年1月至2024年2月这段时间,目的是确定考虑ECOPD住院患者死亡相关因素的符合条件的研究.我们考虑了短期死亡率，长达一年(包括住院死亡率，IHM)和一年以上的长期死亡率，没有时间限制。我们排除了有关重症监护领域的研究。
■我们考虑了38项研究，32和8报告了有关短期和长期死亡率的数据，分别。两项研究考虑了这两个时期。几个因素,有些人已经知道，其他新发现的，进行了评估和讨论。其中一些与COPD的特征和严重程度有关(年龄，身体质量指数,肺损伤)，一些人考虑了对ECOPD的回应。在最后一个背景下，我们专注于生物标志物在预测患者死亡率方面的作用日益增强，尤其是IHM。我们与预后较差相关的因素可能有助于在临床实践中识别有风险的患者，随后,确定个性化的方法。
■全面搜索，本研究涵盖2013年1月至2024年2月这段时间,目的是确定考虑ECOPD住院患者死亡相关因素的符合条件的研究.我们考虑了短期死亡率，长达一年(包括住院死亡率，IHM)和一年以上的长期死亡率，没有时间限制。我们排除了有关重症监护领域的研究。
■我们考虑了38项研究，32和8报告了有关短期和长期死亡率的数据，分别。两项研究考虑了这两个时期。几个因素,有些人已经知道，其他新发现的，进行了评估和讨论。其中一些与COPD的特征和严重程度有关(年龄，身体质量指数,肺损伤)，一些人考虑了对ECOPD的回应。在最后一个背景下，我们专注于生物标志物在预测患者死亡率方面的作用日益增强，尤其是IHM。我们与预后较差相关的因素可能有助于在临床实践中识别有风险的患者，随后,确定个性化的方法。
